{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T11:06:22Z","timestamp":1769943982531,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81560345"],"award-info":[{"award-number":["81560345"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5704-3","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T13:26:14Z","timestamp":1558617974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Huan","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengdong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuhui","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2962-0847","authenticated-orcid":false,"given":"Wenxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"issue":"1","key":"5704_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"5704_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","volume":"30","author":"NK Janzen","year":"2003","unstructured":"Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843\u201352.","journal-title":"Urol Clin North Am"},{"issue":"Suppl 7","key":"5704_CR3","doi-asserted-by":"publisher","first-page":"vii65","DOI":"10.1093\/annonc\/mds227","volume":"23","author":"B Escudier","year":"2012","unstructured":"Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65\u201371.","journal-title":"Ann Oncol"},{"key":"5704_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","volume":"7","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Agarwal N, Beard C, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Cancer Netw. 2009;7:618\u201330.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"8","key":"5704_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","volume":"10","author":"ME Gore","year":"2009","unstructured":"Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of Sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757\u201363.","journal-title":"Lancet Oncol."},{"issue":"6","key":"5704_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5704_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331.","journal-title":"N Engl J Med"},{"issue":"17","key":"5704_CR8","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1016\/j.ejca.2012.05.022","volume":"48","author":"T Powles","year":"2012","unstructured":"Powles T, Sarwar N, Jones R, et al. An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. Eur J Cancer. 2012;48(17):3171\u20136.","journal-title":"Eur J Cancer"},{"issue":"3\u20134","key":"5704_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5489\/cuaj.4398","volume":"11","author":"AA Lalani","year":"2017","unstructured":"Lalani AA, Li H, Heng DYC, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Can Urol Assoc J. 2017;11(3\u20134):112\u20137.","journal-title":"Can Urol Assoc J"},{"key":"5704_CR10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials."},{"issue":"1","key":"5704_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"6","key":"5704_CR12","first-page":"727","volume":"18","author":"GA Wells","year":"2014","unstructured":"Wells GA, Shea BJ, O'Connell D, et al. The Newcastle\u2013Ottawa scale (nos) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric. 2014;18(6):727\u201334.","journal-title":"Appl Eng Agric"},{"issue":"2","key":"5704_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00280-016-3093-8","volume":"78","author":"JH Kim","year":"2016","unstructured":"Kim JH, Park I, Lee JL, et al. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol. 2016;78(2):325\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"5704_CR14","first-page":"515","volume":"21","author":"SA Byfield","year":"2015","unstructured":"Byfield SA, McPheeters JT, Burton TM, et al. Persistence and compliance among U.S. patients receiving Pazopanib or Sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis. J Manag Care Spec Pharm. 2015;21(6):515\u201322.","journal-title":"J Manag Care Spec Pharm."},{"issue":"4","key":"5704_CR15","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/j.clgc.2016.12.005","volume":"15","author":"SK Pal","year":"2017","unstructured":"Pal SK, Ghate SR, Li N, et al. Real-World Survival Outcomes and Prognostic Factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER-Medicare database analysis. Clin Genitourin Cancer. 2017;15(4):e573\u201382.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"5704_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.juro.2014.07.011","volume":"193","author":"M Santoni","year":"2015","unstructured":"Santoni M, Conti A, Porta C, et al. Sunitinib, Pazopanib or Sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J Urol. 2015;193(1):41\u20137.","journal-title":"J Urol"},{"issue":"11","key":"5704_CR17","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-017-0628-2","volume":"34","author":"NJ Vogelzang","year":"2017","unstructured":"Vogelzang NJ, Pal SK, Ghate SR, et al. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting Pazopanib or Sunitinib treatment: a retrospective Medicare claims analysis. Adv Ther. 2017;34(11):2452\u201365.","journal-title":"Adv Ther"},{"issue":"1","key":"5704_CR18","first-page":"37","volume":"21","author":"RN Hansen","year":"2015","unstructured":"Hansen RN, Hackshaw MD, Nagar SP, et al. Health care costs among renal Cancer patients using Pazopanib and Sunitinib. J Manag Care Spec Pharm. 2015;21(1):37\u201344 44a-d.","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"5704_CR19","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1185\/03007995.2015.1081881","volume":"31","author":"PN Racsa","year":"2015","unstructured":"Racsa PN, Whisman TR, Worley K, et al. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients. Curr Med Res Opin. 2015;31(10):1933\u201340.","journal-title":"Curr Med Res Opin"},{"issue":"25","key":"5704_CR20","doi-asserted-by":"publisher","first-page":"37599","DOI":"10.18632\/oncotarget.9229","volume":"7","author":"M Bianconi","year":"2016","unstructured":"Bianconi M, Faloppi L, Loretelli C, et al. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget. 2016;7(25):37599\u2013607.","journal-title":"Oncotarget."},{"issue":"14","key":"5704_CR21","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","volume":"32","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for Pazopanib versus Sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412\u20138.","journal-title":"J Clin Oncol"},{"key":"5704_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ejca.2016.06.016","volume":"65","author":"JM Ruiz-Morales","year":"2016","unstructured":"Ruiz-Morales JM, Swierkowski M, Wells JC, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. Eur J Cancer. 2016;65:102\u20138.","journal-title":"Eur J Cancer"},{"issue":"4","key":"5704_CR23","first-page":"331","volume":"17","author":"J Kucharczyk","year":"2017","unstructured":"Kucharczyk J, Mandalapu K, Satti S, et al. Outcomes of patients with late-relapse metastatic renal cell carcinoma treated with targeted therapies: a single institution experience. Ochsner J. 2017;17(4):331\u20134.","journal-title":"Ochsner J"},{"issue":"suppl_5","key":"5704_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/annonc\/mdx371.039","volume":"28","author":"M Ekenel","year":"2017","unstructured":"Ekenel M, Aydin E, Cil I, et al. Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: two Turkish hospital experience, a retrospective comparative case series study. Ann Oncol. 2017;28(suppl_5):367.","journal-title":"Ann Oncol"},{"issue":"15","key":"5704_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.e16085","volume":"34","author":"S Chow","year":"2016","unstructured":"Chow S, Pillai MR, Galvis V, et al. 10 year outcomes from a single-Centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC). J Clin Oncol. 2016;34(15):e16085.","journal-title":"J Clin Oncol"},{"issue":"11","key":"5704_CR26","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","volume":"26","author":"JL Lee","year":"2015","unstructured":"Lee JL, Kim MK, Park I, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus two weeks on and one week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol. 2015;26(11):2300\u20135.","journal-title":"Ann Oncol"},{"issue":"6","key":"5704_CR27","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084\u20139.","journal-title":"Eur J Cancer"},{"issue":"7","key":"5704_CR28","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/cncr.29888","volume":"122","author":"JL Beaumont","year":"2016","unstructured":"Beaumont JL, Salsman JM, Diaz J, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122(7):1108\u201315.","journal-title":"Cancer."},{"issue":"3","key":"5704_CR29","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/S1470-2045(16)00081-4","volume":"17","author":"M Granovetter","year":"2016","unstructured":"Granovetter M. Benefits of pazopanib over sunitinib for renal cell carcinoma. Lancet Oncol. 2016;17(3):e93.","journal-title":"Lancet Oncol"},{"key":"5704_CR30","first-page":"346","volume":"31","author":"MD Hackshaw","year":"2013","unstructured":"Hackshaw MD, Diaz J, Huang C, et al. Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study. J Clin Oncol. 2013;31(6_suppl:346.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5704_CR31","first-page":"46","volume":"21","author":"TE Delea","year":"2015","unstructured":"Delea TE, Amdahl J, Diaz J, et al. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. J Manag Care Spec Pharm. 2015;21(1):46\u201354.","journal-title":"J Manag Care Spec Pharm."},{"issue":"4","key":"5704_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.25122\/jml-2018-0069","volume":"11","author":"A Liviu Preda","year":"2018","unstructured":"Liviu Preda A, Galieta Minc\u0103 D. Cost-Effectiveness Analysis of Treatment for Metastatic Renal Carcinoma in Romania. J Med Life. 2018;11(4):306\u201311.","journal-title":"J Med Life"},{"issue":"3","key":"5704_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.clinthera.2017.01.017","volume":"39","author":"S Capri","year":"2017","unstructured":"Capri S, Porta C, Delea TE, et al. Cost-effectiveness of Pazopanib versus Sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian National Health Service Perspective. Clin Ther. 2017;39(3):567\u201380.","journal-title":"Clin Ther"},{"issue":"6","key":"5704_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175920","volume":"12","author":"J Amdahl","year":"2017","unstructured":"Amdahl J, Diaz J, Sharma A, et al. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PLoS One. 2017;12(6):e0175920.","journal-title":"PLoS One"},{"issue":"4","key":"5704_CR35","doi-asserted-by":"publisher","first-page":"A220","DOI":"10.1016\/j.jval.2012.03.1187","volume":"15","author":"P Anaya","year":"2012","unstructured":"Anaya P, Delea TE, Pichardo P, et al. Cost effectiveness analysis based on progression free survival (PFS) of Pazopanib versus Sunitinib for the treatment of advanced renal cell carcinoma (ARCC) in the Mexican context. Value Health. 2012;15(4):A220.","journal-title":"Value Health"},{"issue":"5","key":"5704_CR36","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/bjc.2013.832","volume":"110","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Bukowski RM, Rini BI, et al. Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer. 2014;110(5):1125\u201332.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5704-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T21:04:03Z","timestamp":1694898243000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5704-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5704"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5704-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]},"assertion":[{"value":"29 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"489"}}